Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. [electronic resource]
Producer: 20191028Description: 482-491 p. digitalISSN:- 1527-3350
- Adult
- Aminoisobutyric Acids
- Antiviral Agents -- administration & dosage
- Carbamates -- administration & dosage
- Cyclopropanes
- Drug Therapy, Combination
- Genotype
- Hepatitis C -- classification
- Hepatitis C, Chronic -- drug therapy
- Heterocyclic Compounds, 4 or More Rings -- administration & dosage
- Humans
- Lactams, Macrocyclic
- Leucine -- analogs & derivatives
- Macrocyclic Compounds -- administration & dosage
- Proline -- analogs & derivatives
- Quinoxalines
- Risk Assessment
- Sofosbuvir -- administration & dosage
- Sulfonamides -- administration & dosage
- Sustained Virologic Response
- United States
- United States Food and Drug Administration
- Viral Nonstructural Proteins -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.